The University of Texas System

Washington University

Xiankai Sun

Xiaoxu Li

Dipanjan Pan

Karen L Wooley

Michael John Welch

Yaowu Hao

Matthew L Becker

Huafeng Fang

Sina Moeendarbari

Raffaella Rossin

Jeffrey L Turner

Amit Kumar

Jung-Mo Ahn

Zoltan Kovacs

Jian Zhou

Jer-Tsong Hsieh

John-Stephen Taylor

John Stephen Taylor

In one aspect, radioactive nanoparticles are described herein. In some embodiments, a radioactive nanoparticle described herein comprises a metal nanoparticle core, an outer metal shell disposed over the metal nanoparticle core, and a metallic radioisotope disposed within the metal nanoparticle core or within the outer metal shell. In some cases, the radioactive nanoparticle has a size of about 30-500 nm in three dimensions. In addition, in some embodiments, the radioactive nanoparticle further comprises an inner metal shell disposed between the metal nanoparticle core and the outer metal shell. The metal nanoparticle core, outer metal shell, and inner metal shell of the radioactive nanoparticle can have various metallic compositions.

Methods of performing brachytherapy

Radioactive nanoparticles and methods of making and using the same

In some aspects, the present invention provides novel ligands, which may be used to make novel dual-modality imaging agents, for example, for PET and MRI imaging. In further aspects, by the present disclosure also provides methods of use and methods of preparation of the novel ligands, metal complexes, and imaging agents thereof.

Molecular design toward dual-modality probes for radioisotope-based imaging (PET or SPECT) and MRI

A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2'-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50.

Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids ('PNAs') with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer

Compositions, methods of using and methods of making a cyclic peptide analog imaging agent that includes at least portions of a peptide or protein that binds specifically to the GLP-1 receptor (GLP-1R) and the cyclic analog has one or more conformational restrictions including, but not limited to, lactam bridges, disulfide bridges, hydrocarbon bridges, and their combinations, salts and derivatives thereof wherein the cyclic analog is more stable than a non-cyclic analog when incubated in the presence of enzymes that degrade GLP-1 and have an increased serum half-live, wherein the cyclic analog comprises at least a portion of a GLP-1 peptide or at least a portion of an Exendin peptide salts, derivatives or combinations thereof.

Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells

The present invention provides methods for imaging and the treatment of cancer. In certain embodiments, a polyarginine (e.g., R11) may be used to selectively image prostate or bladder cells (e.g., a metastatic prostate cancer). In other embodiments, a DOC-2/DAB2 peptide, optionally conjugated to a cell permeable peptide (e.g., R11) may be used to treat a cancer, such as prostate cancer.

Imaging and therapeutic targeting of prostate and bladder tissues

Growing community of inventors

Coppell, TX, United States of America

Xiankai Sun